(VIANEWS) – Good morning! Another day of trading is almost starting and here’s today’s list of stocks that have had significant trading activity in the US premarket session.

The three most active and biggest winners today are STERIS, Xenetic Biosciences, and Zai Lab.

Rank Financial Asset Price Premarket
Change
Updated (EST)
1 STERIS (STE) 265.50 11.13% 2022-01-06 06:28:32
2 Xenetic Biosciences (XBIO) 1.39 6.92% 2022-01-06 07:04:08
3 Zai Lab (ZLAB) 56.95 5.17% 2022-01-06 04:37:45
4 CDW Corporation (CDW) 213.91 5.1% 2022-01-06 06:39:27
5 Deutsche Bank (DB) 13.82 4.94% 2022-01-06 07:21:18
6 TherapeuticsMD (TXMD) 0.42 4.51% 2022-01-06 07:18:40
7 Fresenius Medical Care AG (FMS) 32.84 4.19% 2022-01-06 04:21:28
8 JD.com (JD) 65.31 3.63% 2022-01-06 07:27:56
9 Futu Holdings (FUTU) 37.31 3.38% 2022-01-06 07:32:29
10 Sabre Corporation (SABR) 9.25 3.24% 2022-01-06 07:29:42

The three most active and biggest losers today are MicroVision, Identiv, and Sypris Solutions.

Rank Financial Asset Price Premarket
Change
Updated (EST)
1 MicroVision (MVIS) 4.39 -11.13% 2022-01-06 07:28:41
2 Identiv (INVE) 24.01 -4.87% 2022-01-06 04:12:24
3 Sypris Solutions (SYPR) 2.29 -4.18% 2022-01-06 04:36:29
4 Towers Watson & Co (TW) 88.00 -3.76% 2022-01-06 04:18:09
5 Alnylam Pharmaceuticals (ALNY) 149.96 -3.31% 2022-01-06 06:23:23
6 Genmab (GMAB) 36.27 -3.12% 2022-01-06 06:47:44
7 First Majestic Silver (AG) 10.35 -2.63% 2022-01-06 04:38:02
8 Akamai Technologies (AKAM) 112.60 -2.49% 2022-01-06 07:23:54
9 Riot Blockchain (RIOT) 20.91 -2.47% 2022-01-06 07:33:46
10 Marathon (MARA) 28.96 -2.23% 2022-01-06 07:28:16

Most Active Premarket Winners today

1. STERIS (STE) – Premarket: 11.13%

NYSE Composite ended the session with STERIS falling 2.55% to $238.91 on Thursday, after four successive sessions in a row of losses. NYSE Composite slid 1.29% to $17,112.61, following the last session’s downward trend on what was an all-around down trend exchanging session today.

STERIS’s last close was $238.91, 0.66% higher than its 52-week high of $237.35.

The company’s growth estimates for the present quarter and the next is 23% and 13.9%, respectively.

STERIS’s Revenue

Year-on-year quarterly revenue growth grew by 44.8%, now sitting on 3.41B for the twelve trailing months.

Volatility

STERIS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.05%, a positive 0.34%, and a positive 1.18%, respectively.

STERIS’s highest amplitude of average volatility was 0.66% (last week), 1.05% (last month), and 1.18% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

STERIS’s stock is considered to be oversold (<=20).

STERIS’s Stock Yearly Top and Bottom Value

STERIS’s stock is valued at $238.91 at 07:34 EST, higher than its 52-week high of $237.35.

STERIS’s Moving Average

STERIS’s value is above its 50-day moving average of $226.39 and way above its 200-day moving average of $209.62.

More news about STERIS.

2. Xenetic Biosciences (XBIO) – Premarket: 6.92%

NASDAQ Composite ended the session with Xenetic Biosciences sliding 4.41% to $1.30 on Thursday, after four consecutive sessions in a row of losses. NASDAQ Composite slid 3.34% to $15,100.17, after two sequential sessions in a row of losses, on what was a very bearish trend trading session today.

Volume

Today’s last reported volume for Xenetic Biosciences is 132634, 55.42% below its average volume of 297556.

Xenetic Biosciences’s last close was $1.30, 77.11% below its 52-week high of $5.68.

Xenetic Biosciences’s Sales

Xenetic Biosciences’s sales growth is 72.4% for the current quarter and a decline by 33.8% for the next. The company’s growth estimates for the present quarter and the next is 90% and 6.3%, respectively.

Xenetic Biosciences’s Revenue

Year-on-year quarterly revenue growth grew by 154.7%, now sitting on 746.09k for the twelve trailing months.

Volatility

Xenetic Biosciences’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.14%, a negative 0.18%, and a positive 3.45%, respectively.

Xenetic Biosciences’s highest amplitude of average volatility was 4.06% (last week), 3.45% (last month), and 3.45% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Xenetic Biosciences’s stock is considered to be oversold (<=20).

Xenetic Biosciences’s Stock Yearly Top and Bottom Value

Xenetic Biosciences’s stock is valued at $1.30 at 07:34 EST, way below its 52-week high of $5.68 and above its 52-week low of $1.21.

Xenetic Biosciences’s Moving Average

Xenetic Biosciences’s value is way under its 50-day moving average of $1.64 and way below its 200-day moving average of $2.19.

More news about Xenetic Biosciences.

3. Zai Lab (ZLAB) – Premarket: 5.17%

NASDAQ Composite ended the session with Zai Lab dropping 9.14% to $54.15 on Thursday, after two consecutive sessions in a row of losses. NASDAQ Composite dropped 3.34% to $15,100.17, after two consecutive sessions in a row of losses, on what was a very down trend exchanging session today.

Volume

Today’s last reported volume for Zai Lab is 602631, 0.04% below its average volume of 602901.

Zai Lab’s last close was $54.15, 72.02% under its 52-week high of $193.54.

Zai Lab’s Revenue

Year-on-year quarterly revenue growth grew by 235.9%, now sitting on 86.78M for the twelve trailing months.

Volatility

Zai Lab’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.86%, a negative 0.87%, and a positive 2.81%, respectively.

Zai Lab’s highest amplitude of average volatility was 5.33% (last week), 3.04% (last month), and 2.81% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Zai Lab’s stock is considered to be overbought (>=80).

Zai Lab’s Stock Yearly Top and Bottom Value

Zai Lab’s stock is valued at $54.15 at 07:34 EST, way under its 52-week low of $84.54.

Zai Lab’s Moving Average

Zai Lab’s worth is way below its 50-day moving average of $102.86 and way below its 200-day moving average of $141.83.

More news about Zai Lab.

4. CDW Corporation (CDW) – Premarket: 5.1%

NASDAQ Composite ended the session with CDW Corporation falling 2.21% to $203.53 on Thursday while NASDAQ Composite dropped 3.34% to $15,100.17.

CDW Corporation’s last close was $203.53, 0.14% below its 52-week high of $203.82.

CDW Corporation’s Sales

CDW Corporation’s sales growth is 12.5% for the current quarter and 2.9% for the next. The company’s growth estimates for the present quarter and the next is 12% and 3.3%, respectively.

CDW Corporation’s Revenue

Year-on-year quarterly revenue growth grew by 11.4%, now sitting on 20.24B for the twelve trailing months.

Volatility

CDW Corporation’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.39%, a negative 0.18%, and a positive 1.31%, respectively.

CDW Corporation’s highest amplitude of average volatility was 0.39% (last week), 1.32% (last month), and 1.31% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

CDW Corporation’s stock is considered to be overbought (>=80).

CDW Corporation’s Stock Yearly Top and Bottom Value

CDW Corporation’s stock is valued at $203.53 at 07:34 EST, under its 52-week high of $203.82 and way above its 52-week low of $125.46.

CDW Corporation’s Moving Average

CDW Corporation’s worth is above its 50-day moving average of $188.41 and way above its 200-day moving average of $180.71.

More news about CDW Corporation.

5. Deutsche Bank (DB) – Premarket: 4.94%

NYSE Composite ended the session with Deutsche Bank dropping 0.38% to $13.17 on Thursday, after four consecutive sessions in a row of losses. NYSE Composite fell 1.29% to $17,112.61, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Deutsche Bank’s last close was $13.17, 14.15% under its 52-week high of $15.34.

The company’s growth estimates for the ongoing quarter is 200% and a drop 76.2% for the next.

Deutsche Bank’s Revenue

Year-on-year quarterly revenue growth grew by 3.5%, now sitting on 24.79B for the twelve trailing months.

Volatility

Deutsche Bank’s last week, last month’s, and last quarter’s current intraday variation average was 1.94%, 0.16%, and 1.57%, respectively.

Deutsche Bank’s highest amplitude of average volatility was 2.03% (last week), 1.28% (last month), and 1.57% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Deutsche Bank’s stock is considered to be oversold (<=20).

Deutsche Bank’s Stock Yearly Top and Bottom Value

Deutsche Bank’s stock is valued at $13.17 at 07:34 EST, way below its 52-week high of $15.34 and way higher than its 52-week low of $10.08.

Deutsche Bank’s Moving Average

Deutsche Bank’s value is above its 50-day moving average of $12.83 and higher than its 200-day moving average of $12.95.

Previous days news about Deutsche Bank

  • Unicredit has flexibility for banco BPM deal, deutsche bank says. According to Bloomberg Quint on Wednesday, 5 January, "UniCredit SpA’s new shareholder remuneration policy gives it leeway to pursue an acquisition like a takeover of domestic rival Banco BPM SpA, according to a Deutsche Bank AG analyst.", "Significantly leveraging buybacks to reward investors increases Milan-based UniCredit’s flexibility in mergers and acquisitions, Deutsche Bank analyst Giovanni Razzoli wrote in a report Wednesday. "
  • BNP eyes top European equity spot after deutsche bank deal. According to Bloomberg Quint on Wednesday, 5 January, "BNP Paribas SA is aiming to become Europe’s top equities-trading player after completing the integration of Deutsche Bank AG’s prime-brokerage assets."

More news about Deutsche Bank.

6. TherapeuticsMD (TXMD) – Premarket: 4.51%

NASDAQ Composite ended the session with TherapeuticsMD dropping 8.18% to $0.40 on Thursday, after two successive sessions in a row of losses. NASDAQ Composite dropped 3.34% to $15,100.17, after two consecutive sessions in a row of losses, on what was a very negative trend trading session today.

Volume

Today’s last reported volume for TherapeuticsMD is 7387240, 27.41% above its average volume of 5797810.

TherapeuticsMD’s last close was $0.40, 85.4% under its 52-week high of $2.75.

TherapeuticsMD’s Sales

TherapeuticsMD’s sales growth is 33.7% for the ongoing quarter and 29.3% for the next. The company’s growth estimates for the present quarter and the next is 16.7% and 40%, respectively.

TherapeuticsMD’s Revenue

Year-on-year quarterly revenue growth grew by 114.9%, now sitting on 84.79M for the twelve trailing months.

Volatility

TherapeuticsMD’s last week, last month’s, and last quarter’s current intraday variation average was a positive 6.26%, a negative 0.25%, and a positive 6.01%, respectively.

TherapeuticsMD’s highest amplitude of average volatility was 7.85% (last week), 6.69% (last month), and 6.01% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

TherapeuticsMD’s stock is considered to be oversold (<=20).

TherapeuticsMD’s Stock Yearly Top and Bottom Value

TherapeuticsMD’s stock is valued at $0.40 at 07:34 EST, way below its 52-week high of $2.75 and higher than its 52-week low of $0.37.

TherapeuticsMD’s Moving Average

TherapeuticsMD’s worth is way under its 50-day moving average of $0.66 and way under its 200-day moving average of $1.00.

More news about TherapeuticsMD.

7. Fresenius Medical Care AG (FMS) – Premarket: 4.19%

NYSE Composite ended the session with Fresenius Medical Care AG falling 2.96% to $31.52 on Thursday, after four successive sessions in a row of losses. NYSE Composite dropped 1.29% to $17,112.61, following the last session’s downward trend on what was an all-around down trend exchanging session today.

Fresenius Medical Care AG’s last close was $31.52, 27.26% under its 52-week high of $43.33.

Fresenius Medical Care AG’s Sales

Fresenius Medical Care AG’s sales growth is a negative 5% for the ongoing quarter and 27.6% for the next. The company’s growth estimates for the current quarter and the next is a negative 26% and a negative 24.7%, respectively.

Fresenius Medical Care AG’s Revenue

Year-on-year quarterly revenue growth declined by 5.2%, now sitting on 17.34B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Fresenius Medical Care AG’s stock is considered to be overbought (>=80).

Fresenius Medical Care AG’s Stock Yearly Top and Bottom Value

Fresenius Medical Care AG’s stock is valued at $31.52 at 07:34 EST, way below its 52-week high of $43.33 and above its 52-week low of $29.71.

Fresenius Medical Care AG’s Moving Average

Fresenius Medical Care AG’s value is below its 50-day moving average of $33.36 and way under its 200-day moving average of $37.59.

More news about Fresenius Medical Care AG.

8. JD.com (JD) – Premarket: 3.63%

NASDAQ Composite ended the session with JD.com sliding 1.84% to $63.02 on Thursday, after five consecutive sessions in a row of losses. NASDAQ Composite fell 3.34% to $15,100.17, after two successive sessions in a row of losses, on what was a very down trend exchanging session today.

JD.com’s last close was $63.02, 41.8% under its 52-week high of $108.29.

JD.com’s Sales

JD.com’s sales growth is 27.4% for the ongoing quarter and 25.8% for the next. The company’s growth estimates for the present quarter and the next is a negative 39.6% and a negative 39.1%, respectively.

JD.com’s Revenue

Year-on-year quarterly revenue growth grew by 39%, now sitting on 802.77B for the twelve trailing months.

Volatility

JD.com’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.71%, a negative 1.23%, and a positive 2.48%, respectively.

JD.com’s highest amplitude of average volatility was 2.71% (last week), 2.64% (last month), and 2.48% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

JD.com’s stock is considered to be overbought (>=80).

JD.com’s Stock Yearly Top and Bottom Value

JD.com’s stock is valued at $63.02 at 07:34 EST, way below its 52-week high of $108.29 and above its 52-week low of $61.65.

JD.com’s Moving Average

JD.com’s worth is way below its 50-day moving average of $81.33 and way under its 200-day moving average of $77.58.

More news about JD.com.

9. Futu Holdings (FUTU) – Premarket: 3.38%

NASDAQ Composite ended the session with Futu Holdings falling 3.5% to $36.09 on Thursday, after five successive sessions in a row of losses. NASDAQ Composite slid 3.34% to $15,100.17, after two sequential sessions in a row of losses, on what was a very bearish trend exchanging session today.

Futu Holdings’s last close was $36.09, 82.33% below its 52-week high of $204.25.

The company’s growth estimates for the ongoing quarter and the next is 406.2% and 236%, respectively.

Futu Holdings’s Revenue

Year-on-year quarterly revenue growth grew by 131.3%, now sitting on 5.56B for the twelve trailing months.

Volatility

Futu Holdings’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.94%, a positive 0.01%, and a positive 5.38%, respectively.

Futu Holdings’s highest amplitude of average volatility was 4.15% (last week), 5.90% (last month), and 5.38% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Futu Holdings’s stock is considered to be overbought (>=80).

Futu Holdings’s Stock Yearly Top and Bottom Value

Futu Holdings’s stock is valued at $36.09 at 07:34 EST, way under its 52-week high of $204.25 and higher than its 52-week low of $35.49.

Futu Holdings’s Moving Average

Futu Holdings’s worth is way below its 50-day moving average of $61.75 and way under its 200-day moving average of $112.43.

More news about Futu Holdings.

10. Sabre Corporation (SABR) – Premarket: 3.24%

NASDAQ Composite ended the session with Sabre Corporation sliding 3.76% to $8.96 on Thursday while NASDAQ Composite slid 3.34% to $15,100.17.

Sabre Corporation’s last close was $8.96, 46.92% under its 52-week high of $16.88.

Sabre Corporation’s Sales

Sabre Corporation’s sales growth is 67.7% for the current quarter and 66.3% for the next. The company’s growth estimates for the current quarter and the next is 35.4% and 42.9%, respectively.

Sabre Corporation’s Revenue

Year-on-year quarterly revenue growth declined by 50.3%, now sitting on 1B for the twelve trailing months.

Volatility

Sabre Corporation’s last week, last month’s, and last quarter’s current intraday variation average was 3.81%, 0.37%, and 4.00%, respectively.

Sabre Corporation’s highest amplitude of average volatility was 4.04% (last week), 4.45% (last month), and 4.00% (last quarter), respectively.

Sabre Corporation’s Stock Yearly Top and Bottom Value

Sabre Corporation’s stock is valued at $8.96 at 07:34 EST, way below its 52-week high of $16.88 and way above its 52-week low of $7.05.

Sabre Corporation’s Moving Average

Sabre Corporation’s value is below its 50-day moving average of $9.84 and way below its 200-day moving average of $12.24.

More news about Sabre Corporation.

Most Active Premarket Losers Today

1. MicroVision (MVIS) – Premarket: -11.13%

NASDAQ Composite ended the session with MicroVision falling 12.72% to $4.94 on Thursday, following the last session’s downward trend. NASDAQ Composite fell 3.34% to $15,100.17, after two successive sessions in a row of losses, on what was a very negative trend trading session today.

MicroVision’s last close was $4.94, 82.36% below its 52-week high of $28.00.

The company’s growth estimates for the current quarter and the next is a negative 200% and a negative 200%, respectively.

MicroVision’s Revenue

Year-on-year quarterly revenue growth grew by 12.4%, now sitting on 2.34M for the twelve trailing months.

Volatility

MicroVision’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.35%, a negative 0.89%, and a positive 4.51%, respectively.

MicroVision’s highest amplitude of average volatility was 8.54% (last week), 4.95% (last month), and 4.51% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

MicroVision’s stock is considered to be overbought (>=80).

MicroVision’s Stock Yearly Top and Bottom Value

MicroVision’s stock is valued at $4.94 at 07:34 EST, way under its 52-week high of $28.00 and way above its 52-week low of $2.88.

MicroVision’s Moving Average

MicroVision’s value is way under its 50-day moving average of $8.59 and way below its 200-day moving average of $13.52.

Previous days news about MicroVision

  • After declining over 75%, microvision bounces off support Monday: technical analysis. According to Business Insider on Monday, 3 January, "Fears of COVID-19 variant omicron have MicroVision up 11.78% for the day at $5.60 at publication time."

More news about MicroVision.

2. Identiv (INVE) – Premarket: -4.87%

NASDAQ Composite ended the session with Identiv sliding 1.25% to $25.24 on Thursday, after five consecutive sessions in a row of losses. NASDAQ Composite dropped 3.34% to $15,100.17, after two successive sessions in a row of losses, on what was a very down trend exchanging session today.

Identiv’s last close was $25.24, 0.04% under its 52-week high of $25.25.

Identiv’s Sales

Identiv’s sales growth is 19.6% for the ongoing quarter and 11.9% for the next. The company’s growth estimates for the current quarter and the next is 400% and 180%, respectively.

Identiv’s Revenue

Year-on-year quarterly revenue growth grew by 17%, now sitting on 100.09M for the twelve trailing months.

Volatility

Identiv’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.39%, a positive 0.09%, and a positive 2.55%, respectively.

Identiv’s highest amplitude of average volatility was 4.51% (last week), 2.99% (last month), and 2.55% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Identiv’s stock is considered to be overbought (>=80).

Identiv’s Stock Yearly Top and Bottom Value

Identiv’s stock is valued at $25.24 at 07:34 EST, under its 52-week high of $25.25 and way higher than its 52-week low of $6.82.

Identiv’s Moving Average

Identiv’s worth is way higher than its 50-day moving average of $21.21 and way above its 200-day moving average of $16.96.

More news about Identiv.

3. Sypris Solutions (SYPR) – Premarket: -4.18%

NASDAQ Composite ended the session with Sypris Solutions falling 3.63% to $2.39 on Thursday, after three sequential sessions in a row of losses. NASDAQ Composite slid 3.34% to $15,100.17, after two successive sessions in a row of losses, on what was a very negative trend trading session today.

Volume

Today’s last reported volume for Sypris Solutions is 84305, 46.64% below its average volume of 158009.

Sypris Solutions’s last close was $2.39, 69.71% below its 52-week high of $7.89.

Sypris Solutions’s Sales

Sypris Solutions’s sales growth is 5.8% for the present quarter and a decline by 20% for the next.

Sypris Solutions’s Revenue

Year-on-year quarterly revenue growth grew by 15.9%, now sitting on 92.25M for the twelve trailing months.

Volatility

Sypris Solutions’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.42%, a negative 2.15%, and a positive 3.63%, respectively.

Sypris Solutions’s highest amplitude of average volatility was 3.63% (last week), 4.17% (last month), and 3.63% (last quarter), respectively.

Sypris Solutions’s Stock Yearly Top and Bottom Value

Sypris Solutions’s stock is valued at $2.39 at 07:34 EST, way under its 52-week high of $7.89 and way higher than its 52-week low of $1.28.

Sypris Solutions’s Moving Average

Sypris Solutions’s value is way below its 50-day moving average of $3.66 and way under its 200-day moving average of $3.46.

More news about Sypris Solutions.

4. Towers Watson & Co (TW) – Premarket: -3.76%

NASDAQ Composite ended the session with Towers Watson & Co falling 2.81% to $91.44 on Thursday, after five consecutive sessions in a row of losses. NASDAQ Composite dropped 3.34% to $15,100.17, after two successive sessions in a row of losses, on what was a very bearish trend exchanging session today.

Towers Watson & Co’s last close was $91.44, 7.87% below its 52-week high of $99.25.

Towers Watson & Co’s Sales

Towers Watson & Co’s sales growth is 22.2% for the ongoing quarter and 16.5% for the next. The company’s growth estimates for the ongoing quarter and the next is 26.7% and 20.6%, respectively.

Towers Watson & Co’s Revenue

Year-on-year quarterly revenue growth grew by 24.7%, now sitting on 1.03B for the twelve trailing months.

Volatility

Towers Watson & Co’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.38%, a negative 0.08%, and a positive 1.16%, respectively.

Towers Watson & Co’s highest amplitude of average volatility was 3.38% (last week), 1.31% (last month), and 1.16% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Towers Watson & Co’s stock is considered to be overbought (>=80).

Towers Watson & Co’s Stock Yearly Top and Bottom Value

Towers Watson & Co’s stock is valued at $91.44 at 07:34 EST, under its 52-week high of $99.25 and way above its 52-week low of $59.35.

Towers Watson & Co’s Moving Average

Towers Watson & Co’s value is higher than its 50-day moving average of $90.82 and above its 200-day moving average of $84.46.

More news about Towers Watson & Co.

5. Alnylam Pharmaceuticals (ALNY) – Premarket: -3.31%

NASDAQ Composite ended the session with Alnylam Pharmaceuticals sliding 6.14% to $155.09 on Thursday, after two sequential sessions in a row of losses. NASDAQ Composite fell 3.34% to $15,100.17, after two sequential sessions in a row of losses, on what was a very negative trend trading session today.

Alnylam Pharmaceuticals’s last close was $155.09, 26.84% under its 52-week high of $212.00.

Alnylam Pharmaceuticals’s Sales

Alnylam Pharmaceuticals’s sales growth is 74.6% for the ongoing quarter and 46.7% for the next. The company’s growth estimates for the present quarter and the next is 28% and 23.9%, respectively.

Alnylam Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth grew by 112.1%, now sitting on 687.53M for the twelve trailing months.

Volatility

Alnylam Pharmaceuticals’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.83%, a positive 0.83%, and a positive 3.07%, respectively.

Alnylam Pharmaceuticals’s highest amplitude of average volatility was 3.38% (last week), 3.96% (last month), and 3.07% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Alnylam Pharmaceuticals’s stock is considered to be overbought (>=80).

Alnylam Pharmaceuticals’s Stock Yearly Top and Bottom Value

Alnylam Pharmaceuticals’s stock is valued at $155.09 at 07:34 EST, way below its 52-week high of $212.00 and way higher than its 52-week low of $124.00.

Alnylam Pharmaceuticals’s Moving Average

Alnylam Pharmaceuticals’s value is way under its 50-day moving average of $186.64 and below its 200-day moving average of $169.03.

More news about Alnylam Pharmaceuticals.

6. Genmab (GMAB) – Premarket: -3.12%

NASDAQ Composite ended the session with Genmab sliding 2.95% to $37.44 on Thursday, after three sequential sessions in a row of losses. NASDAQ Composite slid 3.34% to $15,100.17, after two successive sessions in a row of losses, on what was a very down trend exchanging session today.

Genmab’s last close was $37.44, 23.7% below its 52-week high of $49.07.

Genmab’s Sales

Genmab’s sales growth is a negative 63.6% for the present quarter and 22.8% for the next. The company’s growth estimates for the current quarter is a negative 86.1% and positive 569.2% for the next.

Genmab’s Revenue

Year-on-year quarterly revenue growth grew by 34%, now sitting on 7.91B for the twelve trailing months.

Volatility

Genmab’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.40%, a positive 0.70%, and a positive 1.73%, respectively.

Genmab’s highest amplitude of average volatility was 0.80% (last week), 1.92% (last month), and 1.73% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Genmab’s stock is considered to be overbought (>=80).

Genmab’s Stock Yearly Top and Bottom Value

Genmab’s stock is valued at $37.44 at 07:34 EST, way below its 52-week high of $49.07 and way higher than its 52-week low of $30.10.

Genmab’s Moving Average

Genmab’s worth is way below its 50-day moving average of $42.45 and under its 200-day moving average of $41.10.

More news about Genmab.

7. First Majestic Silver (AG) – Premarket: -2.63%

NYSE Composite ended the session with First Majestic Silver dropping 3.01% to $10.63 on Thursday while NYSE Composite dropped 1.29% to $17,112.61.

Volume

Today’s last reported volume for First Majestic Silver is 5096650, 17.69% above its average volume of 4330460.

First Majestic Silver’s last close was $10.63, 55.73% under its 52-week high of $24.01.

The company’s growth estimates for the current quarter is a negative 50% and positive 200% for the next.

First Majestic Silver’s Revenue

Year-on-year quarterly revenue growth grew by 342%, now sitting on 497.55M for the twelve trailing months.

Volatility

First Majestic Silver’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.62%, a negative 0.33%, and a positive 1.72%, respectively.

First Majestic Silver’s highest amplitude of average volatility was 1.12% (last week), 1.36% (last month), and 1.72% (last quarter), respectively.

First Majestic Silver’s Stock Yearly Top and Bottom Value

First Majestic Silver’s stock is valued at $10.63 at 07:34 EST, way under its 52-week high of $24.01 and way above its 52-week low of $9.62.

First Majestic Silver’s Moving Average

First Majestic Silver’s value is way under its 50-day moving average of $12.32 and way below its 200-day moving average of $14.09.

More news about First Majestic Silver.

8. Akamai Technologies (AKAM) – Premarket: -2.49%

NASDAQ Composite ended the session with Akamai Technologies dropping 1.26% to $115.48 on Thursday while NASDAQ Composite fell 3.34% to $15,100.17.

Akamai Technologies’s last close was $115.48, 7.55% below its 52-week high of $124.91.

Akamai Technologies’s Sales

Akamai Technologies’s sales growth is 7.4% for the ongoing quarter and 5.7% for the next. The company’s growth estimates for the ongoing quarter and the next is 6.1% and 7.5%, respectively.

Akamai Technologies’s Revenue

Year-on-year quarterly revenue growth grew by 7.3%, now sitting on 3.33B for the twelve trailing months.

Volatility

Akamai Technologies’s last week, last month’s, and last quarter’s current intraday variation average was 0.13%, 0.57%, and 1.04%, respectively.

Akamai Technologies’s highest amplitude of average volatility was 0.35% (last week), 0.97% (last month), and 1.04% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Akamai Technologies’s stock is considered to be overbought (>=80).

Akamai Technologies’s Stock Yearly Top and Bottom Value

Akamai Technologies’s stock is valued at $115.48 at 07:34 EST, below its 52-week high of $124.91 and way above its 52-week low of $92.64.

Akamai Technologies’s Moving Average

Akamai Technologies’s worth is above its 50-day moving average of $108.19 and above its 200-day moving average of $110.08.

Previous days news about Akamai Technologies

  • Akamai technologies whale trades spotted. According to Benzinga on Monday, 3 January, "Someone with a lot of money to spend has taken a bullish stance on Akamai Technologies (NASDAQ:AKAM).", "Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $110.0 to $120.0 for Akamai Technologies over the last 3 months."

More news about Akamai Technologies.

9. Riot Blockchain (RIOT) – Premarket: -2.47%

NASDAQ Composite ended the session with Riot Blockchain dropping 12.06% to $21.44 on Thursday while NASDAQ Composite slid 3.34% to $15,100.17.

Riot Blockchain’s last close was $21.44, 73.03% under its 52-week high of $79.50.

The company’s growth estimates for the present quarter and the next is 700% and 125%, respectively.

Riot Blockchain’s Revenue

Year-on-year quarterly revenue growth grew by 1668.7%, now sitting on 65.3M for the twelve trailing months.

Volatility

Riot Blockchain’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.35%, a negative 1.24%, and a positive 5.00%, respectively.

Riot Blockchain’s highest amplitude of average volatility was 5.09% (last week), 4.01% (last month), and 5.00% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Riot Blockchain’s stock is considered to be oversold (<=20).

Riot Blockchain’s Stock Yearly Top and Bottom Value

Riot Blockchain’s stock is valued at $21.44 at 07:34 EST, way under its 52-week high of $79.50 and way above its 52-week low of $8.90.

Riot Blockchain’s Moving Average

Riot Blockchain’s worth is way below its 50-day moving average of $31.38 and way under its 200-day moving average of $35.49.

More news about Riot Blockchain.

10. Marathon (MARA) – Premarket: -2.23%

NASDAQ Composite ended the session with Marathon dropping 13.21% to $29.62 on Thursday while NASDAQ Composite dropped 3.34% to $15,100.17.

Marathon’s last close was $29.62, 64.51% below its 52-week high of $83.45.

Marathon’s Revenue

Year-on-year quarterly revenue growth grew by 6091.1%, now sitting on 92.83M for the twelve trailing months.

Volatility

Marathon’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.09%, a negative 1.61%, and a positive 5.56%, respectively.

Marathon’s highest amplitude of average volatility was 1.47% (last week), 4.73% (last month), and 5.56% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Marathon’s stock is considered to be oversold (<=20).

Marathon’s Stock Yearly Top and Bottom Value

Marathon’s stock is valued at $29.62 at 07:34 EST, way under its 52-week high of $83.45 and way above its 52-week low of $5.14.

Marathon’s Moving Average

Marathon’s worth is way below its 50-day moving average of $51.69 and way under its 200-day moving average of $37.76.

Previous days news about Marathon

  • Marathon digital says its Bitcoin production more than doubled in December over previous month. According to Benzinga on Tuesday, 4 January, "U.S. mining companies like Marathon Chain and Riot BlockChain Inc. (NASDAQ:RIOT) have played a key role in the surge in North America’s Bitcoin mining.", "Bitcoin (CRYPTO: BTC) mining company Marathon Digital Holdings Inc. (NASDAQ:MARA) reported a 147% month-over-month increase in its Bitcoin production in December."
  • Investor alert: kirby mcinerney LLP reminds investors that a class action lawsuit has been filed on behalf of marathon digital holdings, inc. (mara) investors and encourages investors to contact the firm before February 15, 2022. According to Benzinga on Tuesday, 4 January, "NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) — The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Nevada on behalf of those who acquired Marathon Digital Holdings, Inc. f/k/a Marathon Patent Group, Inc. ("Marathon" or the "Company") (NASDAQ:MARA) securities from October 13, 2020 through November 15, 2021, inclusive (the "Class Period"). ", "The lawsuit alleges throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Beowulf Joint Venture, as it related to the Hardin Facility, implicated potential regulatory violations, including U.S. securities law violations; and (ii) as a result, the Beowulf Joint Venture subjected Marathon to a heightened risk of regulatory scrutiny."
  • MARA securities fraud: hagens berman, national trial attorneys, encourages marathon digital holdings (mara) investors to contact firm's attorneys, securities fraud class action pending. According to Benzinga on Monday, 3 January, "We’re focused on investors’ losses and proving Marathon misled investors about the legality of funding the Hardin Facility," said Reed Kathrein, the Hagens Berman partner leading the investigation.", "In connection with that joint venture, Marathon entered into a series of agreements with multiple parties to design and build the Hardin Facility, issuing 6 million shares to the parties of those agreements."
  • Rosen, A TOP ranked LAW firm, encourages marathon digital holdings, inc. f/k/a marathon patent group, inc. investors with losses to secure counsel before important February 15 deadline in securities class action – MARA. According to Benzinga on Monday, 3 January, "SO WHAT: If you purchased Marathon securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.", "NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) — WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Marathon Digital Holdings, Inc. f/k/a Marathon Patent Group, Inc. (NASDAQ:MARA) between October 13, 2020 and November 15, 2021, inclusive (the "Class Period"), of the important February 15, 2022 lead plaintiff deadline."
  • Bragar eagel & squire, p.c. reminds investors that class action lawsuits have been filed against sleep number, marathon digital, and redwire and encourages investors to contact the firm. According to Benzinga on Wednesday, 5 January, "NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Sleep Number Corporation (NASDAQ:SNBR), Marathon Digital Holdings, Inc. (NASDAQ:MARA), and Redwire Corporation (NYSE:RDW). ", "For more information on the Marathon Digital class action go to: https://bespc.com/cases/MARA"

More news about Marathon.

Stay up to date with our premarket winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here